Background: Induction-maintenance therapy is a treatment regime where patients are prescribed an intense course of treatment for a short period of time (the induction phase), followed by a simplified long-term regimen (maintenance). Since induction therapy has a significantly higher chance of pill fatigue than maintenance therapy, patients might take drug holidays during this period. Without guidance, patients who choose to stop therapy will each be making individual decisions, with no scientific basis.
Methods: We use mathematical modelling to investigate the effect of imperfect adherence during the inductive phase. We address the following research questions: 1. Can we theoretically determine the maximal length of a possible drug holiday and the minimal number of doses that must subsequently be taken while still avoiding resistance? 2. How many drug holidays can be taken during the induction phase?
Results: For a 180 day therapeutic program, a patient can take several drug holidays, but then has to follow each drug holiday with a strict, but fairly straightforward, drug-taking regimen. Since the results are dependent upon the drug regimen, we calculated the length and number of drug holidays for all fifteen protease-sparing triple-drug cocktails that have been approved by the US Food and Drug Administration.
Conclusions: Induction therapy with partial adherence is tolerable, but the outcome depends on the drug cocktail. Our theoretical predictions are in line with recent results from pilot studies of short-cycle treatment interruption strategies and may be useful in guiding the design of future clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833165 | PMC |
| http://dx.doi.org/10.1186/1471-2334-10-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oral Antibacterial Drug Prescribing in Primary Care Out-of-Hours Services: A Scoping Review.
Antibiotics (Basel)
January 2025
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK.
Background/objectives: The rapid spread of antimicrobial resistance (AMR) presents a critical threat to global health. Primary care plays a significant role in this crisis, with oral antibacterial drugs among the most prescribed medications. Antibacterial prescribing rates are often high and complicated in out-of-hours (OOH) services, including weekdays outside regular hours, weekends, and holidays, potentially exacerbating AMR.
View Article and Find Full Text PDFMedication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.
J Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFConcerns Over Vuse e-Cigarette Digital Marketing and Implications for Public Health Regulation: Content Analysis.
JMIR Form Res
December 2024
REACH Lab, Department of Pediatrics, Division of Adolescent Medicine, Stanford University, Palo Alto, CA, United States.
Background: Electronic cigarettes (e-cigarettes) are the most used form of tobacco products among adolescents and young adults, and Vuse is one of the most popular brands of e-cigarettes among US adolescents. In October 2021, Vuse Solo became the first e-cigarette brand to receive marketing granted orders (MGOs) from the US Food and Drug Administration (FDA), authorizing its marketing and their tobacco-flavored pods. Vuse Ciro and Vuse Vibe, and their tobacco-only ("original") e-liquids, were authorized for marketing in May 2022 and Vuse Alto tobacco-flavored devices were authorized in July 2024.
View Article and Find Full Text PDFRelative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation Study.
Clin Pharmacokinet
January 2025
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Article Synopsis
- The study focuses on the patterns of medication adherence among gout patients using allopurinol and how these patterns affect serum urate levels and clinical outcomes.
- It finds that while occasional missed doses may not drastically impact urate control, consistently taking breaks of more than three days significantly lowers the likelihood of achieving adequate urate levels.
- The research emphasizes the importance of understanding individual medication-taking habits to improve treatment outcomes for gout patients.
Topical 5-fluorouracil 1% as first-line therapy for giant ocular surface squamous neoplasia.
J Fr Ophtalmol
December 2024
Cornea and Refractive Surgery Department, Asociación para Evitar la Ceguera en México, I.A.P., Mexico City, Mexico.
Purpose: To evaluate the clinical outcomes of topical 5-fluorouracil (5-FU) 1% as first-line therapy for giant ocular surface squamous neoplasia (OSSN).
Materials And Methods: This was a non-comparative cohort study. We included patients with biopsy-proven giant OSSN in a tertiary-care setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!